CL2015003706A1 - Composiciones vacunales bivalentes y su uso para la terapia de tumores - Google Patents

Composiciones vacunales bivalentes y su uso para la terapia de tumores

Info

Publication number
CL2015003706A1
CL2015003706A1 CL2015003706A CL2015003706A CL2015003706A1 CL 2015003706 A1 CL2015003706 A1 CL 2015003706A1 CL 2015003706 A CL2015003706 A CL 2015003706A CL 2015003706 A CL2015003706 A CL 2015003706A CL 2015003706 A1 CL2015003706 A1 CL 2015003706A1
Authority
CL
Chile
Prior art keywords
vaccine compositions
tumor therapy
bivalent vaccine
bivalent
tumor
Prior art date
Application number
CL2015003706A
Other languages
English (en)
Inventor
Ramirez Belinda Sanchez
Rivera Arianna Yglesias
Perez Amelia Gutierrez
Suarez Narjara Gonzalez
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Publication of CL2015003706A1 publication Critical patent/CL2015003706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2015003706A 2013-08-02 2015-12-22 Composiciones vacunales bivalentes y su uso para la terapia de tumores CL2015003706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2013000110A CU24299B1 (es) 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
CL2015003706A1 true CL2015003706A1 (es) 2016-07-22

Family

ID=51453541

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003706A CL2015003706A1 (es) 2013-08-02 2015-12-22 Composiciones vacunales bivalentes y su uso para la terapia de tumores

Country Status (24)

Country Link
US (2) US20160166667A1 (es)
EP (1) EP3028714B1 (es)
JP (1) JP6479002B2 (es)
KR (1) KR20160018665A (es)
CN (1) CN105407916A (es)
AR (1) AR097172A1 (es)
AU (1) AU2014298978B2 (es)
CA (1) CA2916552C (es)
CL (1) CL2015003706A1 (es)
CU (1) CU24299B1 (es)
EA (1) EA034194B1 (es)
ES (1) ES2894075T3 (es)
HK (1) HK1220141A1 (es)
IL (1) IL243879B (es)
MX (1) MX2016001459A (es)
MY (1) MY194889A (es)
PE (1) PE20160174A1 (es)
PH (1) PH12016500224A1 (es)
SG (1) SG11201600084WA (es)
TN (1) TN2015000557A1 (es)
TW (1) TWI554281B (es)
UA (1) UA116154C2 (es)
WO (1) WO2015014327A1 (es)
ZA (1) ZA201601328B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018234783A1 (en) * 2017-03-15 2019-10-10 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4306697A1 (de) * 1993-03-04 1994-09-08 Merck Patent Gmbh Mittel und Verfahren zur immunologischen Bestimmung von Diphenhydramin und dessen Metaboliten
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase

Also Published As

Publication number Publication date
NZ716579A (en) 2021-10-29
CU20130110A7 (es) 2015-03-30
JP2016525555A (ja) 2016-08-25
CA2916552A1 (en) 2015-02-05
MY194889A (en) 2022-12-21
WO2015014327A1 (es) 2015-02-05
TW201521765A (zh) 2015-06-16
SG11201600084WA (en) 2016-02-26
EA201690309A1 (ru) 2016-06-30
KR20160018665A (ko) 2016-02-17
UA116154C2 (uk) 2018-02-12
CN105407916A (zh) 2016-03-16
ES2894075T3 (es) 2022-02-11
AU2014298978B2 (en) 2019-05-23
HK1220141A1 (zh) 2017-04-28
EP3028714A1 (en) 2016-06-08
ZA201601328B (en) 2017-11-29
CA2916552C (en) 2020-03-31
TN2015000557A1 (en) 2017-04-06
IL243879B (en) 2019-09-26
BR112016002174A2 (pt) 2017-08-01
US20160166667A1 (en) 2016-06-16
PH12016500224A1 (en) 2016-05-16
AU2014298978A1 (en) 2016-02-25
EP3028714B1 (en) 2021-09-29
CU24299B1 (es) 2017-12-08
TWI554281B (zh) 2016-10-21
MX2016001459A (es) 2017-01-05
JP6479002B2 (ja) 2019-03-06
US20190275132A1 (en) 2019-09-12
AR097172A1 (es) 2016-02-24
PE20160174A1 (es) 2016-04-20
EA034194B1 (ru) 2020-01-16
IL243879A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
BR112016021626A2 (pt) indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
BR112015023217A2 (pt) sistema de bandagem para terapia lumínica
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112015023679A2 (pt) composições e métodos para imunoterapia
BR112016013333A2 (pt) composição para cuidado oral
BR112015021732A2 (pt) dispositivo para uso terapêutico
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
BR112015025408A2 (pt) combinações de droga para tratar câncer
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
BR112015016548A2 (pt) polimixinas , composições , métodos de preparação e métodos de uso
FR3014969B1 (fr) Fixation temporaire
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
DK3068505T3 (da) Spillesystem og -fremgangsmåde
CL2015001689A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
IL244354B (en) Flu vaccine and treatment
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2016001152A1 (es) Vacuna para peces
BR112016004943A2 (pt) aparelho médico e uso
CL2016000998A1 (es) Composición herbaria, procedimiento para su preparación y uso de la misma
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi